Medical News

RSS

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

27 Oct 2009

Child birth to be broadcast live

MomsLikeMe.com, a leading local-moms site, announces that an entire pregnancy is being captured on TwinCities.MomsLikeMe.com. A locally driven online social network for moms, MomsLikeMe.com, is thrilled that Lynsee and Anders will share the experience of having their first child -- including the baby's birth in November -- with the community.

27 Oct 2009

Even one cigarette has serious adverse effects on young adults, says researcher

Even one cigarette has serious adverse effects on young adults, according to research presented by Dr. Stella Daskalopoulou at the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

27 Oct 2009

Inverness Medical Innovations announces its financial results for the third-quarter

Inverness Medical Innovations, Inc., a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended September 30, 2009.

27 Oct 2009

OHA takes step to promote public sector transparency

Today, the Ontario Hospital Association (OHA) has taken a major step to promote public sector transparency and accountability by proposing that the Government of Ontario extend the province's Freedom of Information and Protection of Privacy Act (FOIPPA) to the hospital sector. The OHA represents Ontario's 155 public hospitals.

27 Oct 2009

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

ISO 9001:2008 certification for Kapa Biosystems

Life science reagents supplier Kapa Biosystems announced today that its Research, Development and Manufacturing facility has received ISO 9001:2008 certification from SABS Commercial (Pty) Ltd.

27 Oct 2009

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.

27 Oct 2009

Positive results from Phase II clinical trial of INT-747 announced

Intercept Pharmaceuticals, Inc., today announced positive results from a 165 patient, placebo controlled, double-blind Phase II clinical trial of INT-747 in patients with primary biliary cirrhosis (PBC).

27 Oct 2009

DHS awards cyber security task order to CSC

CSC announced today that the U.S. Department of Homeland Security (DHS) awarded the company a task order to provide information technology infrastructure and cyber support to the National Protection and Programs Directorate's Office of Cyber Security and Communications. The task order was awarded under the Enterprise Acquisition Gateway for Leading Edge Solutions (EAGLE) contract, originally awarded to CSC in July 2006.

27 Oct 2009

Third-quarter fiscal 2009 results announced by Cynosure

Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its third purchase order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry and Information Technology for the national stockpiling plan.

27 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

New Trace Express Viewer software from CDC Software

CDC Software Corporation, a global provider of enterprise software applications and services, today announced the availability of Trace Express Viewer, a new solution for its Ross ERP Lot Trace application that enables easier use, faster access and immediate forward and backward trace functionality to identify suspect materials and assist in the disposition of finished goods in the event of a product recall - key functionalities for product safety and compliance.

27 Oct 2009

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and KOKEN Co., Ltd., a leading atelocollagen company, announced today that Alnylam has granted KOKEN a non-exclusive worldwide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family.

27 Oct 2009

ZYTO announces financial results for the third quarter of 2009

ZYTO Corp announces an EBITDA profit of $234,021 for the third quarter of 2009, up 325% as compared to the same period last year. Total revenue for the third quarter of 2009 was $1,106,260, up from $532,548 in revenue for the third quarter of 2008.

27 Oct 2009

Helicos Biosciences reports operational highlights for the third quarter of 2009

Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.

27 Oct 2009

Bioconnect Systems to present clinical study of Optiflow device at ASN Meeting in San Diego

Bioconnect Systems, Inc. announced today that data from the Company's first clinical study will be presented this week at the ASN Meeting in San Diego. Bioconnect’s implant platform, the Optiflow™, enhances a surgeon’s ability to create precise vascular connections.

27 Oct 2009

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Life Technologies Corporation (NASDAQ:LIFE) today announced results for its third quarter ended September 30, 2009. Non-GAAP revenue for the third quarter was $805 million, an increase of 3 percent over third quarter revenue of $784 million in 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 27 Oct 2009

Climate change and public health: only fives states have published public health response plans, says study

Trust for America's Health (TFAH) released a new report today that finds only five states have published a strategic climate change plan that includes a public health response. This includes planning for health challenges and emergencies expected to develop from natural disasters, pollution, and infectious diseases as temperatures and sea levels rise.

27 Oct 2009

Medical News

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

Child birth to be broadcast live

Even one cigarette has serious adverse effects on young adults, says researcher

Inverness Medical Innovations announces its financial results for the third-quarter

OHA takes step to promote public sector transparency

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

ISO 9001:2008 certification for Kapa Biosystems

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Positive results from Phase II clinical trial of INT-747 announced

DHS awards cyber security task order to CSC

Third-quarter fiscal 2009 results announced by Cynosure

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

New Trace Express Viewer software from CDC Software

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

ZYTO announces financial results for the third quarter of 2009

Helicos Biosciences reports operational highlights for the third quarter of 2009

Bioconnect Systems to present clinical study of Optiflow device at ASN Meeting in San Diego

Life Technologies reports third quarter 2009 results; non-GAAP and organic revenues increase by 3% and 5%

Climate change and public health: only fives states have published public health response plans, says study

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Dr. Anthony Grice

Building quality into drug development for safer, faster medicines

Latest News